BioAlliance Pharma, a developer of orphan oncology products and supportive care products, has entered a collaboration agreement with a leading vaccine company to develop a vaccine application of its Lauriad mucoadhesive technology. The terms of the agreement were not disclosed.
This research program aims to establish feasibility using Lauriad technology for vaccination, leading to an efficient needle-free administration of this mucoadhesive tablet containing a vaccine antigen.
“This collaboration with one of the world leading vaccine companies shows the potential interest of our innovative Lauriad system for a needle-free vaccination. This is also a major step taken to increase the value of our proprietary Lauriad technology, already validated through three major products of our portfolio: Loramyc and Sitavig, already registered, and Validive, in Phase II clinical development,” said Judith Greciet, chief executive officer of BioAlliance Pharma. “A first successful feasibility would open the way to promising new opportunities in vaccine field with significant market potential worldwide.”